Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis | Zendy

Kristine E. Ensrud | Zendy; Andrea Z. LaCroix | Zendy; John R. Thompson | Zendy; David D. Thompson | Zendy; Richard Eastell | Zendy; David M. Reid | Zendy; Slobodan Vukičević | Zendy; Jane A. Cauley | Zendy; Elizabeth BarrettConnor | Zendy; Róisín Armstrong | Zendy; Francine K. Welty | Zendy; Steven R. Cummings | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis

Author(s) -

Kristine E. Ensrud,

Andrea Z. LaCroix,

John R. Thompson,

David D. Thompson,

Richard Eastell,

David M. Reid,

Slobodan Vukičević,

Jane A. Cauley,

Elizabeth BarrettConnor,

Róisín Armstrong,

Francine K. Welty,

Steven R. Cummings

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.109.924571

Subject(s) - medicine , osteoporosis , postmenopausal osteoporosis , postmenopausal women , intensive care medicine , bone mineral

In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research